scholarly journals Testing for diabetes in hospitalised patients prescribed antipsychotic drugs

2004 ◽  
Vol 185 (2) ◽  
pp. 152-156 ◽  
Author(s):  
David Taylor ◽  
Corina Young ◽  
Raadiyya Esop ◽  
Carol Paton ◽  
Rebecca Walwyn

BackgroundStudies using computer databases suggest that atypical antipsychotic agents are more likely to be associated with diabetes than are conventional drugs.AimsTo discover the extent of testing for diabetes mellitus in hospital in-patients prescribed antipsychotics.MethodPrescription charts were screened to identify patients prescribed antipsychotics. Case notes were then searched for evidence of testing for diabetes.ResultsIn all, 606 patients were prescribed antipsychotics, of whom 250 (41.3%) had evidence of prior testing for diabetes. Patients prescribed atypicals were 40% more likely to have been tested than those prescribed conventional drugs (RR = 1.4, 95% C11.1–1.9). Adjusted odds ratios v. conventional antipsychotics for testing were significantly higher for clozapine (OR = 4.64, 95% C12.42–8.90), olanzapine (OR= 1.85, 95% C11.04–3.30) and antipsychotic polypharmacy (OR= 2.96, 95% C11.59–5.52).ConclusionsTesting for diabetes was undertaken in less than half of the patients studied. Testing was more common in those receiving atypical antipsychotics. Apparent differences in claimed causal association of the use of some antipsychotics with diabetes may in part reflect different rates of testing.

2005 ◽  
Vol 11 ◽  
pp. 31-32
Author(s):  
Shahzad Iqbal ◽  
Faith X. Zhao ◽  
Renuka Tunuguntla ◽  
Mahboob A. Khan ◽  
Deepak Thomas ◽  
...  

2005 ◽  
Vol 11 ◽  
pp. 30-31
Author(s):  
Shahzad Iqbal ◽  
Faith X. Zhao ◽  
Renuka Tunuguntla ◽  
Deepak Thomas ◽  
Mahboob A. Khan ◽  
...  

2014 ◽  
Vol 4 (2) ◽  
pp. 65-72 ◽  
Author(s):  
Anna K Morin

Despite limited supporting evidence, off-label uses of atypical or second generation antipsychotics (particularly olanzapine, quetiapine, and risperidone) are not uncommon. The off-label use of these agents for the treatment of insomnia is the focus of this review. While atypical antipsychotics are associated with a lower risk of tardive dyskinesia, extrapyramidal side effects, and more favorable effects on cognitive deficits and negative symptomatology in schizophrenic patients compared to typical or first generation antipsychotic agents, they are not without risks. Metabolic adverse effects are particularly problematic with atypical antipsychotics, even at doses lower than those used to treat FDA-approved indications. The receptor affinity profiles of most atypical antipsychotic agents promote sedation. The level of H1-histamine receptor blockade is believed to be most associated with somnolence and sedation. Several studies evaluating the safety and efficacy of the atypical antipsychotics quetiapine, olanzapine, and risperidone for the treatment of insomnia were identified and are summarized in this article.


Author(s):  
Beth M. Dubisar ◽  
Steven C. Stoner ◽  
James Reynolds ◽  
Rintu Khan ◽  
Leonard Ramlatchman

Sign in / Sign up

Export Citation Format

Share Document